Hypertrophic cardiomyopathy: Combination of β blockers and verapamil may be risky

von Borja, Javier, Izquierdo, Iñaki, Guindo, Josep
Veröffentlicht 2006

Morning and evening efficacy evaluation of rupatadine (10 and 20 mg), compared with cetirizine 10 mg in perennial allergic rhinitis: a randomized, double-blind, placebo-controlled...

von Marmouz, Farid, Giralt, Josep, Izquierdo, Iñaki
Veröffentlicht 2011

Rupatadine Oral Solution Titration by Body Weight in Paediatric Patients Suffering from Allergic Rhinitis: A Population Pharmacokinetic Study

von Santamaria, Eva, Izquierdo, Iñaki, Valle, Marta
Veröffentlicht in Clin Pharmacol (2021)

Rupatadine oral solution for 2–5-year-old children with allergic rhinitis: a safety, open-label, prospective study

von Santamaría, Eva, Izquierdo, Iñaki, Valle, Marta, Vermeulen, Jan, Potter, Paul
Veröffentlicht in J Asthma Allergy (2018)

PD39 - Application of population pharmacokinetic modeling and simulation in the design of the optimal dose regime of rupatadine in children 2-5 year old children

von Valle, Marta, Estevez, Javier, Martial, Lisa Charlotte, Santamaria, Eva, Izquierdo, Iñaki
Veröffentlicht 2014

Population pharmacokinetic modelling of rupatadine solution in 6–11 year olds and optimisation of the experimental design in younger children

von Santamaría, Eva, Estévez, Javier Alejandro, Riba, Jordi, Izquierdo, Iñaki, Valle, Marta
Veröffentlicht in PLoS One (2017)

Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo-Controlled Trial

von Täubel, Jörg, Ferber, Georg, Fernandes, Sara, Lorch, Ulrike, Santamaría, Eva, Izquierdo, Iñaki
Veröffentlicht in PLoS One (2016)

Clinically relevant effect of rupatadine 20 mg and 10 mg in seasonal allergic rhinitis: a pooled responder analysis

von Mullol, Joaquim, Izquierdo, Iñaki, Okubo, Kimihiro, Canonica, Giorgio Walter, Bousquet, Jean, Valero, Antonio
Veröffentlicht in Clin Transl Allergy (2019)

Higher efficacy of rupatadine 20 mg and 10 mg versus placebo in patients with perennial allergic rhinitis: a pooled responder analysis

von Valero, Antonio, Izquierdo, Iñaki, Kowalski, Marek L., Scadding, Glenis K., Bousquet, Jean, Mullol, Joaquim
Veröffentlicht in Allergy Asthma Clin Immunol (2020)

Rupatadine in Established Treatment Schemes Improves Chronic Spontaneous Urticaria Symptoms and Patients’ Quality of Life: a Prospective, Non-interventional Trial

von Metz, Martin, Weller, Karsten, Neumeister, Claudia, Izquierdo, Iñaki, Bödeker, Rolf-Hasso, Schwantes, Ulrich, Maurer, Marcus
Veröffentlicht in Dermatol Ther (Heidelb) (2015)

O10 - Rupatadine is effective and safe in the treatment of Chronic Spontaneous Urticaria (CSU) in pediatric patients (2-11 years old)

von Potter, Paul, Mitha, Essack, Barkai, Laszlo, Domenech, Alejandro, Santamaria, Eva, Giralt, Josep, Izquierdo, Iñaki, Maurer, Marcus
Veröffentlicht 2014

Rupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double-blind, crossover, repeated dose, placebo-controlled study

von García-Gea, Consuelo, Ballester, Maria Rosa, Martínez, Juan, Antonijoan, Rosa Maria, Donado, Esther, Izquierdo, Iñaki, Barbanoj, Manuel-José
Veröffentlicht 2010

No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a ‘thorough QT/QTc study’ performed according to ICH guidelines

von Donado, Ester, Izquierdo, Iñaki, Pérez, Iñaki, García, Olga, Antonijoan, Rosa Ma, Gich, Ignaci, Solans, Anna, Peña, Juana, Morganroth, Joel, Barbanoj, Manuel J
Veröffentlicht 2010

Rupatadine oral solution improves rhino-conjunctive symptoms control in children with 6-11 years weighing ≥25 kg with persistent allergic rhinitis

von Izquierdo, Iñaki, Potter, Paul, Maspero, Jorge, Vermeulen, Jan, Barkai, Laszlo, Nemeth, Ildiko, Baillieau, Rene, Garde M, Jesus M, Giralt, Josep, Domenech, Alejandro, Nieto, Antonio
Veröffentlicht 2013